Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers

DNA damage processing by mismatch repair (MMR) and/or base excision repair (BER) can determine the therapeutic index following treatment of human cancers using radiation therapy and several classes of chemotherapy drugs. Over the last decade, basic and translational cancer research in DNA repair has led to an increased understanding of how these two DNA repair pathways can modify cytotoxicity to chemotherapy and/or ionizing radiation treatments in both normal and malignant tissues. This Molecular Pathways article provides an overview of the current understanding of mechanisms involved in MMR and BER damage processing, including insights into possible coordination of these two DNA repair pathways after chemotherapy and/or ionizing radiation damage. It also introduces principles of systems biology that have been applied to better understand the complexities and coordination of MMR and BER in processing these DNA damages. Finally, it highlights novel therapeutic approaches to target resistant (or DNA damage tolerant) human cancers using chemical and molecular modifiers of chemotherapy and/or ionizing radiation including poly (ADP-ribose) polymerase inhibitors, methoxyamine and iododeoxyuridine (and the prodrug, 5-iodo-2-pyrimidinone-2'-deoxyribose).

[1]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[2]  P. Peltomäki.  Role of DNA mismatch repair defects in the pathogenesis of human cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Thomas Helleday,et al.  DNA repair pathways as targets for cancer therapy , 2008, Nature Reviews Cancer.

[4]  Allison L. Zulli,et al.  The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity , 2007, Molecular Cancer Therapeutics.

[5]  David M. Wilson,et al.  A quantitative model of human DNA base excision repair. I. Mechanistic insights. , 2002, Nucleic acids research.

[6]  P. Karran.  Mechanisms of tolerance to DNA damaging therapeutic drugs. , 2001, Carcinogenesis.

[7]  M. Saparbaev,et al.  Role of mismatch-specific uracil-DNA glycosylase in repair of 3,N4-ethenocytosine in vivo. , 2004, DNA repair.

[8]  J. Cheadle,et al.  MUTYH-associated polyposis--from defect in base excision repair to clinical genetic testing. , 2007, DNA repair.

[9]  V. Sondak,et al.  Preoperative idoxuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up , 1998, Annals of Surgical Oncology.

[10]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[11]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. de Wind,et al.  Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. , 2000, Cancer research.

[13]  J. Low,et al.  Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology , 2007, Clinical Cancer Research.

[14]  P. Modrich,et al.  DNA mismatch repair: functions and mechanisms. , 2006, Chemical reviews.

[15]  D. Kennedy,et al.  DNA adducts, DNA repair genotype/phenotype and cancer risk. , 2005, Mutation research.

[16]  T. Kinsella,et al.  DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  N. Curtin,et al.  PARP inhibitors for cancer therapy , 2005, Expert Reviews in Molecular Medicine.

[18]  V. O'shea,et al.  Base-excision repair of oxidative DNA damage , 2007, Nature.

[19]  J. Wang,et al.  Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.

[20]  T. Kinsella,et al.  Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  T. Ideker,et al.  Supporting Online Material for A Systems Approach to Mapping DNA Damage Response Pathways , 2006 .

[22]  M. Meyers,et al.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.

[23]  R. Daniel,et al.  The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Jiricny.  The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.

[25]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[26]  J. Tainer,et al.  The intricate structural chemistry of base excision repair machinery: implications for DNA damage recognition, removal, and repair. , 2007, DNA repair.

[27]  T. Kinsella,et al.  Targeting DNA mismatch repair for radiosensitization. , 2001, Seminars in Radiation Oncology.

[28]  R. Plummer,et al.  First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Hwang,et al.  Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. , 2001, Mutation research.

[30]  E. Plummer.  Inhibition of poly(ADP-ribose) polymerase in cancer. , 2006, Current opinion in pharmacology.

[31]  D. Pompliano,et al.  Nat. Rev. Drug Disc. , 2007 .

[32]  V. O’Brien,et al.  Signalling cell cycle arrest and cell death through the MMR System. , 2006, Carcinogenesis.

[33]  Qinguo Zheng,et al.  Role of Postreplicative DNA Mismatch Repair in the Cytotoxic Action of Thioguanine , 1996, Science.

[34]  T. Kinsella,et al.  Schedule-Dependent Drug Effects of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose as an In vivo Radiosensitizer in U251 Human Glioblastoma Xenografts , 2005, Clinical Cancer Research.

[35]  R. Fishel.  Signaling mismatch repair in cancer , 1999, Nature Medicine.

[36]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[37]  K. Loparo,et al.  A conceptual modeling framework for the study of DNA mismatch repair pathway to improve therapeutic gain in cancer treatment , 2007, 2007 IEEE/NIH Life Science Systems and Applications Workshop.

[38]  Tao Yan,et al.  CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. , 2004, Molecular cancer therapeutics.

[39]  Kenneth A Loparo,et al.  Probabilistic modeling of DNA mismatch repair effects on cell cycle dynamics and iododeoxyuridine-DNA incorporation. , 2007, Cancer research.

[40]  P. Hsieh,et al.  ATR Kinase Activation Mediated by MutSα and MutLα in Response to Cytotoxic O6-Methylguanine Adducts , 2006 .

[41]  G. Dianov,et al.  Base excision repair fidelity in normal and cancer cells. , 2006, Mutagenesis.

[42]  T. Kinsella,et al.  Role of MutSα in the Recognition of Iododeoxyuridine in DNA , 2003 .

[43]  A. Drohat,et al.  Excision of 5-Halogenated Uracils by Human Thymine DNA Glycosylase , 2007, Journal of Biological Chemistry.

[44]  K. Brown,et al.  Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. , 2005, Molecular biology of the cell.

[45]  Martin L. Smith,et al.  Manipulation of Base Excision Repair to Sensitize Ovarian Cancer Cells to Alkylating Agent Temozolomide , 2007, Clinical Cancer Research.

[46]  Yuji Seo,et al.  Differential Radiosensitization in DNA Mismatch Repair-Proficient and -Deficient Human Colon Cancer Xenografts with 5-Iodo-2-pyrimidinone-2′-deoxyribose , 2004, Clinical Cancer Research.

[47]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[48]  S. Steinberg,et al.  National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. , 1994, International journal of radiation oncology, biology, physics.

[49]  B. Sokhansanj,et al.  Estimating the Effect of Human Base Excision Repair Protein Variants on the Repair of Oxidative DNA Base Damage , 2006, Cancer Epidemiology Biomarkers & Prevention.

[50]  T. Kinsella,et al.  A Novel Role for DNA Mismatch Repair and the Autophagic Processing of Chemotherapy Drugs in Human Tumor Cells , 2007, Autophagy.

[51]  P. Karran,et al.  Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer , 2008, Nature Reviews Cancer.

[52]  M. Mehta,et al.  Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. , 2004, International journal of radiation oncology, biology, physics.

[53]  T. Kinsella,et al.  Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence , 2006, Molecular Cancer Therapeutics.

[54]  G. Dianov,et al.  CHIP-mediated degradation and DNA damage-dependent stabilization regulate base excision repair proteins. , 2008, Molecular cell.

[55]  Lili Liu,et al.  Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. , 2004, Current opinion in investigational drugs.

[56]  J. Doroshow,et al.  Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient , 2008, Clinical Cancer Research.

[57]  H. Hwang,et al.  Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. , 2003, Cancer research.

[58]  Csaba Szabó,et al.  Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors , 2005, Nature Reviews Drug Discovery.

[59]  M. Veigl,et al.  Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation. , 2001, Cancer research.